	US 12,264,185 B2
	Stabilized BCL9 peptides for treatment of aberrant Wnt signaling
David Zhu, Newton, MA (US)
Assigned to WntRx Pharmaceuticals Inc., Newton, MA (US)
Filed by WntRx Pharmaceuticals Inc., Newton, MA (US)
Filed on Oct. 6, 2022, as Appl. No. 17/938,598.
Application 17/215,698 is a division of application No. 15/766,268, granted, now 10,961,290, issued on Mar. 30, 2021, previously published as PCT/US2016/055589, filed on Oct. 5, 2016.
Application 17/938,598 is a continuation of application No. 17/215,698, filed on Mar. 29, 2021, granted, now 11,498,947.
Claims priority of provisional application 62/237,489, filed on Oct. 5, 2015.
Prior Publication US 2023/0265138 A1, Aug. 24, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/82 (2006.01)

CPC C07K 14/4705 (2013.01) [A61K 38/1709 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/82 (2013.01); A61K 38/00 (2013.01)]

10 Claims

1. A method of manufacturing a polypeptide having a length of 7-14 amino acids, wherein the polypeptide is derived from the HD2 domain of human B-cell CLL/lymphoma 9 (BCL9), the polypeptide is capable of undergoing a reaction to form a hydrocarbon crosslinker, and the polypeptide comprises any sequence selected from:

	(SEQ ID NO: 79)
	LQTLRXaa₁IQRXaa₂L;
	and

	(SEQ ID NO: 82)
	Xaa₁LQXaa₂LRXaa₃IQRXaa₄L

and wherein:

Xaa₁, Xaa₂, Xaa₃, and Xaa₃are each an α-methyl, α-alkenyl amino acid;

the method comprising using solid phase synthesis to generate the polypeptide.